Ashburn, VA, United States of America

Susan VanMeter

This inventor holds 1 USPTO granted patent. Top assignee: Amalive Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Susan VanMeter. Retrieved from https://idiyas.com/inventor/susan-vanmeter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Susan VanMeter: Patent Activity in Hyperammonemia Treatment

Introduction

Susan VanMeter is an inventor associated with Ashburn, Virginia, and Amalive Limited. Her patent work concerns ornithine phenylacetate and its potential use in treating hyperammonemia.

Latest Patents

VanMeter is associated with 1 patent: “Dosages and Uses of Ornithine Phenylacetate for Treating Hyperammonemia.” The disclosure describes doses and methods of administering ornithine phenylacetate to treat or ameliorate hyperammonemia in patients with chronic liver disease, such as cirrhosis. Some embodiments also address patients with hepatic encephalopathy as a complication of liver disease.

Career Highlights

The available information identifies VanMeter’s patent activity in the area of treatments for hyperammonemia and lists Amalive Limited as her company affiliation.

Collaborations

The provided information names Xiaofeng Wang Rears and Jack Tseng as VanMeter’s coworkers. It does not specify their roles in the patent or any particular collaboration.

Conclusion

Susan VanMeter’s identified patent focuses on dosing and administration approaches for ornithine phenylacetate in patients with hyperammonemia, including those with chronic liver disease.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…